Drugs / Single-dose Quadrivalent Influenza Vaccine
Single-dose Quadrivalent Influenza Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03391193 Comparator | Dec 2017 → Mar 2018 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Single-dose Quadrivalent Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03391193 ↗ |
| Modality | Vaccine | “Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal free)” NCT03391193 ↗ |
| Route | Intramuscular | “0.5 mL, intramuscular” NCT03391193 ↗ |